The Trump administration decided against allowing Medicare to pay for obesity drugs, a move that would have given millions of Americans access to the medications but would’ve cost the government billions.
The highly anticipated decision sent shares of obesity drugmakers Eli Lilly & Co. and Novo Nordisk A/S lower.
The Centers for Medicare and Medicaid Services had been weighing a Biden administration proposal that could have expanded coverage of the costly drugs by classifying obesity as a disease. In its announcement Friday, CMS said it may reconsider coverage of these drugs in the future.
Lilly’s shares dropped 2% at 4:42 p.m. in extended New York trading, while Novo’s American depositary receipts were down 1.9%.
Representatives for Lilly and Novo didn’t immediately respond to a request for comment.
In the waning days of Biden’s administration, CMS proposed a regulation that would have allowed Medicare to cover popular new weight-loss drugs like Lilly’s Zepbound and Novo’s Wegovy. The proposal would have reinterpreted a law that prohibits Medicare from covering weight-loss drugs. The rule wasn’t finalized before the Trump administration took office.
While older adults can get the medications to treat other conditions like diabetes or cardiovascular disease, they aren’t covered for weight loss alone. Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis found.
Officials in the Trump administration diverge on the use of weight-loss drugs. Health and Human Services Secretary Robert F. Kennedy Jr. has said there’s no need for them if Americans eat right. Tech billionaire Elon Musk, who’s working with the Trump administration, has lost weight on GLP-1 drugs and supports their use.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
